Strong 2024 sales and earnings growth for Recordati

14 February 2025

Italian pharma major Recordati (RECI: MI) has reported strong preliminary consolidated financial results for 2024, with the firm’s shares edging up 2.3% to 60.40 euros.

Consolidated net revenue for full year 2024 was 2,341.6 million euros ($2.420 million), up 12.4% versus full year 2023 or 9.2% on a like-for-like basis at constant exchange rates (CER). This was driven by strong business momentum across both Specialty & Primary Care and Rare Diseases. The adverse FX impact for full year 2024 was 26.9 million euros (-1.3%).

Adjusted net income was 568.9 million, 24.3% of revenue, up by 8.4% compared to the same period of 2023. Net income was 416.5 million euros, 17.8% of revenue, an increase of 7.0% versus full year 2023, with the higher operating income offset by higher tax rate, financing expenses and amortization charges.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK